Recent study in BLCA revealed that TFAP2C knockdown affected the activation levels of EGFR and NF-κB and enhanced the anti-tumor effects of cisplatin in vivo and in vitro 16. The gene discussed is EGFR; the disease is bladder transitional cell carcinoma.